メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
藤井 昌学
医学部
助教
,
大学院医歯薬学総合研究科
助教
,
医学部
助教
,
医歯薬学域
h-index
392
被引用数
10
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2007
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(26)
類似のプロファイル
(6)
フィンガープリント
Masanori Fujiiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Aberrant DNA Methylation
20%
Acute Exacerbation
20%
Afatinib
20%
Alectinib
20%
Anaplastic Lymphoma Kinase
20%
Anti-tuberculosis Therapy
20%
Axillary Lymph Node Metastasis
20%
Bevacizumab
20%
Bladder Tuberculosis
20%
Cancer Recurrence
20%
Cancer Study
20%
CD26 Expression
20%
Chemoradiotherapy
20%
Complete Response
20%
Coronavirus Disease 2019 Vaccine
20%
CTR1
20%
Differential Diagnosis
20%
Diffuse Alveolar Hemorrhage
20%
DNA Methylation Profile
20%
EGFR mutation
20%
Endobronchial Watanabe Spigot
20%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
20%
First Week
20%
Garcin Syndrome
20%
Gilteritinib
20%
Group Experiences
20%
Idiopathic Interstitial Pneumonia
20%
Idiopathic Pulmonary Hemosiderosis
20%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
20%
Intravenous Immunoglobulin (IVIg)
20%
Lung Abscess
20%
Lung Adenocarcinoma
46%
Lung Cancer
69%
Lymphadenopathy
20%
MET Exon 14
20%
Monotherapy
20%
Non-small Cell Lung Cancer (NSCLC)
48%
Objective Response
23%
Okayama
20%
Partial Response
23%
Prompt Treatment
20%
Regrowth
20%
Serum DNA
20%
Skin Rash
20%
Successful Treatment
26%
TBXAS1
20%
Tepotinib
20%
Therapeutic Effect
20%
Tumor Regression
20%
Urinary Bladder Cancer
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Afatinib
20%
Alectinib
20%
Amrubicin
20%
Anaplastic Lymphoma Kinase
20%
Bevacizumab
20%
Biodistribution
6%
Carboplatin
20%
Chemoradiation Therapy
20%
Chemotherapy
27%
Death Associated Protein Kinase
6%
Diarrhea
9%
Disease
20%
Epidermal Growth Factor Receptor
60%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Fibrosing Alveolitis
11%
Gilteritinib
20%
Group Trial
20%
Heat Shock Protein
6%
Hypoxia
6%
Immunoglobulin
20%
Interstitial Pneumonia
20%
Irinotecan
20%
Luciferase
6%
Lung Cancer
91%
Lung Hemosiderosis
15%
Lung Tuberculosis
20%
Malignant Neoplasm
21%
Median Survival Time
8%
Metalloproteinase
6%
Monotherapy
20%
Neoplasm
43%
Non Small Cell Lung Cancer
100%
Osimertinib
21%
Pleura Mesothelioma
20%
Progression Free Survival
17%
Rash
20%
Retinoblastoma Protein
9%
Retinoic Acid Receptor
11%
Silicosis
20%
Small Cell Lung Cancer
20%
Tepotinib
20%
Therapeutic Effect
20%
Thymidylate Synthase
20%
Toxicity and Intoxication
20%
Tuberculostatic Agent
10%
Tumor Growth
20%
Tumor Microenvironment
20%
Tumor Regression
20%
Tumor Suppressor Protein
6%
Medicine and Dentistry
Anamnesis
5%
Arterial Embolization
20%
Axillary Lymph Node
20%
Bevacizumab
20%
Bleeding
12%
Bronchial Artery
20%
Cancer Recurrence
10%
Carboplatin
20%
Cell Membrane
6%
Chemosensitivity
20%
Chemotherapy
5%
Clinician
5%
Combination Therapy
20%
Computer Assisted Tomography
9%
COVID-19
20%
Exon
20%
Garcin Syndrome
20%
Hemoptysis
20%
Idiopathic Interstitial Pneumonia
20%
Idiopathic Pulmonary Fibrosis
11%
Idiopathic Pulmonary Haemosiderosis
15%
Immunoglobulin
20%
Lung Abscess
20%
Lung Adenocarcinoma
44%
Lung Cancer
44%
Lymph Node Metastasis
20%
Lymphadenopathy
20%
Magnetic Resonance Imaging of the Brain
5%
Median Survival Time
6%
Medical History
5%
Methylation
13%
Minoxidil
20%
Neoplasm
27%
Non Small Cell Lung Cancer
27%
Odds Ratio
6%
Overall Survival
6%
Pemetrexed
6%
Pleura Mesothelioma
20%
Polymerase Chain Reaction
6%
Programmed Cell Death
5%
Progression Free Survival
6%
Promoter Region
20%
Sarcomatoid
6%
Silicosis
20%
Tepotinib
20%
Thymidylate Synthase
20%
Thyroid Antibody
5%
Toxicity and Intoxication
20%
